ASCO® 2022 Clinical Practice Guidelines1
For patients with ER+, HER2-, early-stage, invasive breast cancer
Postmenopausal or age
Premenopausal or age
1. Andre et al. J Clin Oncol. 2022. * for N0 and postmenopausal N1 patients
ASCO® 2022 Clinical Practice Guidelines
ASCO® Guidelines 2022 strongly recommend the Oncotype DX® test based on TAILORx and RxPONDER study results1
• The Oncotype DX® test is strongly recommended for all N0 and postmenopausal N1 patients
• For premenopausal N0 patients the Oncotype DX® test is the only recommended assay
• Recommendation is broad and independent of any clinical risk classification
• Recommendation level is strong and with high evidence quality based on
ASCO® recommendation framework
Service Europe +41 22 715 29 00 | europeansupport@exactsciences.com Exact Sciences International GmbH Neuhofstrasse 22, 6340 Baar, Switzerland 1. Andre et al. J Clin Oncol. 2022.